$319.37
+0.20%Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; aspiration-based thrombectomy systems for vascular applications under the Indigo System brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand, as well as immersive computer-based technologies and immersive therapeutics to promote health, motor function, and cognition under the Real Immersive System brand; and a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and Packing Coil LP brands. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
Chief Accounting Officer
Compensation
$581,467
Chief Financial Officer
Compensation
$706,796
Co-Founder & Director
Compensation
$54,000
Co-Founder, Chairman & Chief Executive Officer
Compensation
$630,467
Co-Founder, Chairman, President & Chief Executive Officer
Compensation
$630,467
Executive Vice President & Chief Information Officer
Executive Vice President of Development & Compliance
Executive Vice President of Operations
Executive Vice President, General Counsel & Secretary
Compensation
$706,467
Investor Relations Officer
President
President of Interventional
During the last 12 months, insiders have sold $9.61M worth of PEN shares, with no buying activity reported.
0
0.00
100
32.82K
-33K
-$33K
0
0.00
4.8K
1.57M
-1.6M
-$1.57M
0
0.00
17.6K
5.19M
-5.2M
-$5.19M
0
0.00
11.4K
2.82M
-2.8M
-$2.82M
No buying activity
Bose Arani
Director
$5.73M
Elsesser Adam
Director, Officer: Ceo
$1.41M
Yuen Maggie
Officer: Chief Financial Officer
$1.33M
Roberts Johanna
Officer: Evp, Gen. Counsel & Secretary
$701K
Grewal Harpreet
Director
$230K
Strong bearish signal with $9.61M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
5 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
PEN - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 29, 2026 | June 18, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 16, 2025 | May 28, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 24, 2024 | June 05, 2024 | 2024 | |
DEF 14A DEF 14A N/A | April 19, 2023 | April 19, 2023 | ||
DEF 14A DEF 14A 2022 N/A | April 20, 2022 | June 01, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 22, 2021 | June 02, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 23, 2020 | June 03, 2020 | 2020 | |
DEF 14A DEF 14A 2018 N/A | April 26, 2019 | December 31, 2018 | 2018 | |
DEF 14A DEF 14A 2018 N/A | April 25, 2018 | June 06, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | April 25, 2017 | April 25, 2017 | 2017 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.